Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB ...Middle East

--Response rate of 56% in patients treated monthly with high dose SEL-212 in DISSOLVE I and 47% in DISSOLVE II --In patients 50 years and older, response rate with high dose SEL-212 was 65% in DISSOLVE I and 48% in DISSOLVE II --75% of subjects in the DISSOLVE I extension phase on active...

Hence then, the article about phase 3 dissolve program of sel 212 in chronic refractory gout meets primary endpoint swedish orphan biovitrum ab was published today ( Tuesday 21/03/2023 - 11:16 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB )

Also on site :

• Go Inside BTS ‘Tonight Show’ Taping, From Fan Jump-Scares to Jimmy Fallon Angling to Be ‘The 8th Member’
• Trump& 039;s Disapproval Rating Hits All-Time High, Fox News Poll Shows
• Lord of the Rings Trilogy Has Many Elements That Are Difficult to Watch in the Modern Day